Isabella Castiglioni

Prof. Isabella Castiglioni

Physics applied to Medicine and Biology, University of Milan-Bicocca, Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
ACAntonio Colaprico
Antonio Colaprico
TSTiago Chedraoui Silva
Tiago Chedraoui Silva
COCatharina Olsen
Catharina Olsen
LGLuciano Garofano
Luciano Garofano
CCClaudia Cava
Claudia Cava
HNHoutan Noushmehr
Houtan Noushmehr
The Cancer Genome Atlas (TCGA) research network has made public a large collection of clinical and molecular phenotypes of more than 10 000 tumor patients across 33 different tumor types. Using this cohort, TCGA has published over 20 marker papers detailing the genomic and epigenomic alterations associated with these tumor types. Although many important discoveries have been made by TCGA's research network, opportunities still exist to implement novel methods, thereby elucidating new biological pathways and diagnostic markers. However, mining the TCGA data presents several bioinformatics challenges, such as data retrieval and integration with clinical data and other molecular data types (e.g. RNA and DNA methylation). We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data. We combined methods from computer science and statistics into the pipeline and incorporated methodologies developed in previous TCGA marker studies and in our own group. Using four different TCGA tumor types (Kidney, Brain, Breast and Colon) as examples, we provide case studies to illustrate examples of reproducibility, integrative analysis and utilization of different Bioconductor packages to advance and accelerate novel discoveries.

1 January 2015 in Theranostics
Verified
Journal Article
Open access
GBGloria Bertoli
Gloria Bertoli
CCClaudia Cava
Claudia Cava
ICIsabella Castiglioni
Isabella Castiglioni
Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as oncogenes or tumor suppressor genes. This review presents the state of the art on the role of miRNAs in the diagnosis, prognosis, and therapy of BC. Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335), and prediction of therapeutic outcomes (i.e., miR-30c, miR-187, and miR-339-5p) and have important roles in the control of BC hallmark functions such as invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs are of interest as new, easily accessible, affordable, non-invasive tools for the personalized management of patients with BC because they are circulating in body fluids (e.g., miR-155 and miR-210). In particular, circulating multiple miRNA profiles are showing better diagnostic and prognostic performance as well as better sensitivity than individual miRNAs in BC. New miRNA-based drugs are also promising therapy for BC (e.g., miR-9, miR-21, miR34a, miR145, and miR150), and other miRNAs are showing a fundamental role in modulation of the response to other non-miRNA treatments, being able to increase their efficacy (e.g., miR-21, miR34a, miR195, miR200c, and miR203 in combination with chemotherapy).

1 March 2021 in Physica Medica
Verified
Journal Article
Closed access
ICIsabella Castiglioni
Isabella Castiglioni
Leonardo RundoLeonardo Rundo
Leonardo Rundo
MCMarina Codari
Marina Codari
GLGiovanni Di Leo
Giovanni Di Leo
CSChristian Salvatore
Christian Salvatore
FSFrancesco Sardanelli
Francesco Sardanelli

22 June 2014 in Neuroinformatics
Verified
Journal Article
Open access
PDF file
TCthe EADC-PET Consortium
the EADC-PET Consortium
PRPasquale Anthony Della Rosa
Pasquale Anthony Della Rosa
CCChiara Cerami
Chiara Cerami
FGFrancesca Gallivanone
Francesca Gallivanone
APAnnapaola Prestia
Annapaola Prestia
DPDaniela Perani
Daniela Perani
[18F]-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) is a widely used diagnostic tool that can detect and quantify pathophysiology, as assessed through changes in cerebral glucose metabolism. [18F]-FDG PET scans can be analyzed using voxel-based statistical methods such as Statistical Parametric Mapping (SPM) that provide statistical maps of brain abnormalities in single patients. In order to perform SPM, a “spatial normalization” of an individual’s PET scan is required to match a reference PET template. The PET template currently used for SPM normalization is based on [15O]-H2O images and does not resemble either the specific metabolic features of [18F]-FDG brain scans or the specific morphological characteristics of individual brains affected by neurodegeneration. Thus, our aim was to create a new [18F]-FDG PET aging and dementia-specific template for spatial normalization, based on images derived from both age-matched controls and patients. We hypothesized that this template would increase spatial normalization accuracy and thereby preserve crucial information for research and diagnostic purposes. We investigated the statistical sensitivity and registration accuracy of normalization procedures based on the standard and new template—at the single-subject and group level—independently for subjects with Mild Cognitive Impairment (MCI), probable Alzheimer’s Disease (AD), Frontotemporal lobar degeneration (FTLD) and dementia with Lewy bodies (DLB). We found a significant statistical effect of the population-specific FDG template-based normalisation in key anatomical regions for each dementia subtype, suggesting that spatial normalization with the new template provides more accurate estimates of metabolic abnormalities for single-subject and group analysis, and therefore, a more effective diagnostic measure.

15 July 2005 in Science
Verified
Journal Article
Closed access
PDF file
ABA. Berti
A. Berti
GBGabriella Bottini
Gabriella Bottini
MGMartina Gandola
Martina Gandola
LPLorenzo Pia
Lorenzo Pia
NSN. Smania
N. Smania
EPE. Paulesu
E. Paulesu
In everyday life, the successful monitoring of behavior requires continuous updating of the effectiveness of motor acts; one crucial step is becoming aware of the movements one is performing. We studied the anatomical distribution of lesions in right-brain–damaged hemiplegic patients, who obstinately denied their motor impairment, claiming that they could move their paralyzed limbs. Denial was associated with lesions in areas related to the programming of motor acts, particularly Brodmann's premotor areas 6 and 44, motor area 4, and the somatosensory cortex. This association suggests that monitoring systems may be implemented within the same cortical network that is responsible for the primary function that has to be monitored.

1 January 2014 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
CSChristian Salvatore
Christian Salvatore
ACAntonio Cerasa
Antonio Cerasa
ICI. Castiglioni
I. Castiglioni
FGFrancesca Gallivanone
Francesca Gallivanone
AAAntonio Augimeri
Antonio Augimeri
AQAldo Quattrone
Aldo Quattrone